Drug intelligence / Profile preview

Pvs230D1-EPA + Matrix-M

Development stage: Unknown
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Pvs230D1-EPA + Matrix-M is a transmission-blocking vaccine candidate for Plasmodium vivax malaria. It consists of Pvs230 domain 1 (Pvs230D1), a recombinant protein from subdomain 1 of native Pvs230 (Val-226 to Gly-427) produced in Pichia pastoris, chemically conjugated to Exoprotein A (EPA) and combined with Matrix-M adjuvant. The vaccine is designed to induce antibodies that can block the transmission of malaria parasites from humans to mosquitoes, thereby interrupting the malaria transmission cycle. It is being developed by the National Institute of Allergy & Infectious Diseases (NIAID).

Targets

Pvs230D1 (Pvs230 domain 1)

Beyond the preview

Go deeper on Pvs230D1-EPA + Matrix-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pvs230D1-EPA + Matrix-M.

Explore the full profile